Choosing Among Treatment Options in Relapsed and Refractory Multiple Myeloma

In this segment, Dr. Ajay Nooka invites Dr. Noopur Raje and Dr. Surbhi Sidana to discuss how they choose among available treatment options in relapsed and refractory multiple myeloma. The panel highlights that decision-making is highly individualized and depends on multiple factors, including prior therapy exposure, depth and duration of response, disease aggressiveness, and patient-specific considerations such as performance status and comorbidities. They also discuss how different therapeutic classes, including cellular therapies, bispecific antibodies, antibody–drug conjugates, and conventional regimens, may be considered based on clinical context and treatment goals. Practical considerations such as toxicity profiles, treatment logistics, and patient preferences also play a key role in guiding selection. This segment emphasizes the complexity of treatment decision-making in multiple myeloma and the importance of tailoring therapy to each patient’s unique clinical situation.